Anastrozole
Arimidex
Anastrozole (Arimidex) is a hormonal & sexual research compound. Non-steroidal aromatase inhibitor — lowers estrogen by blocking testosterone-to-estrogen conversion.
Anastrozole quick facts
| Reported research dose | 0.25mg-1mg |
| Route | Oral |
| Frequency | 2-3x Weekly |
| Half-life | ~48 hrs |
| Forms | Oral |
| Evidence level | Human (established) |
Estrogen control on TRT/cycles — very easy to crash E2, so micro-dose and test bloodwork.
How Anastrozole works
Non-steroidal aromatase inhibitor — lowers estrogen by blocking testosterone-to-estrogen conversion.
Proposed benefits
Researched for libido, hormonal signaling and reproductive / sexual function.
Where to get Anastrozole
Buy Anastrozole at AlgoRx →The evidence for Anastrozole
Graded by what exists behind each claim.
✅ Clinically validated
- Extensive trial data as an approved oncology drug for hormone-receptor-positive breast cancer, including the large ATAC trial. Also studied in men: randomized work in older men with low testosterone showed it raises testosterone by reducing conversion to estradiol.
📊 Correlative data
- Widely used on TRT and cycles to control estradiol. The dominant real-world failure mode is overuse — crashing estradiol produces joint pain, low libido, poor lipids and low mood, and the symptoms of too little estrogen are frequently mistaken for too much.
🧪 Theoretical / extrapolated
- A non-steroidal, reversible aromatase inhibitor: it blocks the enzyme converting testosterone to estradiol.
- Reversibility is the practical distinction from exemestane, which inactivates the enzyme permanently. It also means rebound is possible on abrupt cessation. Estradiol in men is required for bone density, lipids and libido, so the mechanism predicts directly why less is not better.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Anastrozole actually does
Aromatase is CYP19A1, the cytochrome P450 that strips the C19 methyl group off androstenedione and testosterone and aromatizes the A ring, turning them into estrone and estradiol. Anastrozole is a benzyltriazole: the triazole nitrogen coordinates the heme iron in the enzyme's active site, and while it sits there the enzyme cannot process a steroid. The label's own description is a selective non-steroidal aromatase inhibitor that significantly lowers serum estradiol and has no detectable effect on formation of adrenal corticosteroids or aldosterone U.S. Food and Drug Administration 2011.
That last clause is the selectivity claim and it is worth pausing on. Aminoglutethimide, the first-generation inhibitor this class replaced, hit the whole steroidogenic P450 family and required corticosteroid replacement. Anastrozole does not, which is why 1 mg a day is tolerable indefinitely in a way that the old drugs never were.
Reversible, and everything practical follows from that word. The triazole competes; it does not destroy. When drug concentration falls, the same enzyme molecules work again. This is the categorical difference from exemestane, which is a false substrate that the enzyme processes into a reactive intermediate and is then covalently killed by. So on anastrozole the depth of estrogen suppression tracks the plasma concentration, and the plasma concentration is governed by a 50-hour half-life reaching steady state at about 7 days U.S. Food and Drug Administration 2011. Nothing about this drug is fast.
The label puts numbers on the pharmacodynamics: 1 mg daily reduced estradiol by approximately 70% within 24 hours and by approximately 80% after 14 days of daily dosing U.S. Food and Drug Administration 2011. Note that those are two different numbers a week and a half apart, which is the clearest statement anywhere that this drug does not finish working on day one.
Now the part that makes anastrozole a different drug in a male body, and it is why this page exists. In a postmenopausal woman the enzyme's entire substrate supply is adrenal androgen and the only consequence of inhibition is less estrogen. In a man there are two consequences, because estradiol is the dominant negative-feedback signal at the hypothalamus. Block aromatase and estradiol falls; feedback is released; LH rises; the testis makes more testosterone; and the extra testosterone is fresh substrate for the partially inhibited enzyme. It is a loop, not a switch. That loop is exactly what Leder 2004 measured, and it is also why the drug behaves completely differently in a man whose axis is already shut down by exogenous testosterone — there, the LH arm cannot fire, and all that is left is estradiol suppression.
Cell, rodent, human — and where it stops
Step one, the registration population, which is women. In ATAC the label records the adverse-event profile of 1 mg daily in 3,092 postmenopausal women with early breast cancer: fractures 10%, arthralgia 15%, hot flashes 36%, hypercholesterolemia 9% and ischemic cardiovascular events 4% U.S. Food and Drug Administration 2011. The cholesterol comparison is the informative one, because it is against an active comparator: elevated serum cholesterol in 9% on anastrozole versus 3.5% on tamoxifen, which is a difference in what the two drugs do to the liver rather than evidence that anastrozole raises cholesterol on its own.
Step two, the first male trial, 12 weeks, and the numbers are the ones to know. Leder 2004 randomized 37 men aged 62–74 with screening testosterone under 350 ng/dL, double-blind, to anastrozole 1 mg daily (n = 12), 1 mg twice weekly (n = 11) or placebo (n = 14) for 12 weeks. Bioavailable testosterone rose from 99 ± 31 to 207 ± 65 ng/dL on daily dosing and from 115 ± 37 to 178 ± 55 on twice weekly (P < 0.001 versus placebo for both). Total testosterone rose from 343 ± 61 to 572 ± 139 ng/dL and from 397 ± 106 to 520 ± 91. Estradiol fell from 26 ± 8 to 17 ± 6 pg/mL and from 27 ± 8 to 17 ± 5. LH rose from 5.1 to 7.9 and from 4.1 to 7.2 U/L. Hematocrit, quality of life, erectile function score and prostate symptom score did not change; PSA rose in the twice-weekly arm only (1.7 ± 1.0 to 2.2 ± 1.5 ng/mL, P = 0.031).
Read the estradiol number against the label's. The label promises about 80% suppression at 14 days in postmenopausal women U.S. Food and Drug Administration 2011. In men on the same 1 mg dose, estradiol fell about 35% — 26 to 17 pg/mL Leder 2004. Same drug, same dose, less than half the suppression, because the substrate supply is much larger and rising. That single comparison is the most useful thing on this page for anyone titrating.
Step three, a year instead of twelve weeks, and the effect fades. Burnett-Bowie 2009 randomized 88 men aged 60 and over to 1 mg daily or placebo for 1 year. Testosterone rose from 11.2 ± 3.3 to 18.2 ± 4.8 nmol/L at month 3 (p < 0.0001) and bioavailable testosterone from 2.7 ± 0.8 to 5.4 ± 1.7 nmol/L — and then both peaked at month 3 and declined by month 12, remaining above baseline but no longer at the three-month level. Estradiol fell from 55.8 ± 15.4 to 42.2 ± 13.6 pmol/L and stayed there. The trial's own conclusion is the part nobody quotes: body composition and strength did not change, and neither did PSA, prostate symptoms, hematocrit or lipids.
Step four, the bone trial, which is where the cost is. Burnett-Bowie 2009 followed 69 men aged 60+ for a year on 1 mg daily. Testosterone went from 319 ± 93 to 524 ± 139 ng/dL at month 3 and settled at 474 ± 145 at one year; estradiol fell from 15 ± 4 to 12 ± 4 pg/mL. Posterior-anterior spine bone mineral density decreased against placebo (P = 0.0014) — 1.121 ± 0.141 to 1.102 ± 0.138 g/cm² on anastrozole while placebo went up, 1.180 ± 0.145 to 1.189 ± 0.146. And the detail that matters for monitoring: bone turnover markers were not affected. The authors concluded that aromatase inhibition does not improve skeletal health in aging men.
Step five, the reassuring one. Dougherty 2005 measured fasting lipids, CRP, IL-6, ICAM-1, VCAM-1 and HOMA in the same 37 men and found no significant effect on any of them over 12 weeks, with one signal worth keeping: a positive correlation between the change in triglycerides and the change in estradiol (P = 0.04). Lower estradiol, lower triglycerides, in that cohort.
The obstacle, and it is the whole page. Every male trial above used older men with low testosterone and an intact hypothalamic-pituitary-testicular axis, at 1 mg daily or 1 mg twice weekly. The population reading this uses 0.25 to 1 mg alongside exogenous testosterone, where the axis is already suppressed. In that setting the LH-mediated testosterone rise — the entire benefit arm of the three trials above — cannot happen, and what remains is the estradiol suppression and the bone cost. No trial has ever studied anastrozole in a man on exogenous testosterone, and no trial has studied any dose below 1 mg twice weekly in men at all.
Anastrozole pharmacokinetics — how much of it actually gets in
Route: oral, and food does not matter. The label permits dosing with or without food; maximum plasma concentrations typically occur within 2 hours under fasted conditions U.S. Food and Drug Administration 2011.
The half-life is 50 hours and it governs every practical decision on this page. Plasma concentrations approach steady state at about 7 days of once-daily dosing U.S. Food and Drug Administration 2011. Do the arithmetic that follows. A change in dose does not express itself for roughly a week, so an estradiol drawn 48 hours after a change is measuring the old dose. Washout after stopping takes about five half-lives, roughly 10 days. And an every-other-day habit at 0.25–0.5 mg still accumulates: with a 50-hour half-life, roughly half of each dose is still present when the next one is taken, so “every other day” is not a rest, it is a lower steady state reached on the same one-week timetable.
What clears it. Hepatic metabolism accounts for approximately 85% of anastrozole elimination; renal elimination accounts for approximately 10% of total clearance U.S. Food and Drug Administration 2011. So this is a liver drug, and the kidney is a minor route — the reverse of most of the compounds on this site.
The interaction fact that matters most here is a negative one. In vitro, anastrozole inhibited reactions catalyzed by CYP1A2, 2C8/9 and 3A4, and had no inhibitory effect on CYP2A6 or CYP2D6 U.S. Food and Drug Administration 2011. That CYP2D6 exemption is directly relevant to this cohort, because tamoxifen depends on CYP2D6 to generate its active metabolite endoxifen. Anastrozole run alongside tamoxifen does not blunt that activation the way an SSRI would. It is a real, checkable pharmacology point in a space that usually argues about this from anecdote.
What would have to be true, and how you would know it was not
Five predictions with a marker, a direction and a window. Two of them cut hard against the compound.
1. Estradiol should fall, on the right assay, at the right time. Draw Estradiol, Sensitive (LC/MS-MS) — not the standard immunoassay, which is unreliable at the concentrations this drug produces — at baseline and at 14 days, because steady state takes about 7 days U.S. Food and Drug Administration 2011 and the label's own suppression figure moves from 70% at 24 hours to 80% at 14 days. Expected magnitude in a man is the male-trial number, roughly a third off at 1 mg daily Leder 2004, not the label's 80%.
2. Total Testosterone and LH & FSH separate the two populations, and this is the single most useful draw on the page. In a man with an intact axis, expect total testosterone up by roughly 60% and LH up by roughly half again over 12 weeks Leder 2004. In a man on exogenous testosterone, expect LH and FSH to stay at the floor and total testosterone not to move, because the feedback loop that produces the rise is already broken. If someone on TRT reports that anastrozole raised their testosterone, the mechanism for that does not exist and the number needs repeating.
3. The prediction that cuts against it: spine bone density will fall, and bone turnover markers will not warn you. Burnett-Bowie 2009 is the trial to know: one year at 1 mg daily in older men, PA spine BMD down against placebo, P = 0.0014, while bone turnover markers were not affected. So Osteocalcin is worth drawing precisely because the published expectation is that it stays normal — a normal turnover marker on this drug is not reassurance, and only a DEXA at baseline and 12–24 months answers the question.
4. The second prediction that cuts against it: whatever you gain, expect less of it at a year than at three months. Burnett-Bowie 2009 found testosterone peaked at month 3 and declined by month 12 while still on the same dose, and that body composition and strength did not change at all over the year. So a 12-week testosterone result is not a durable result, and a 12-week feeling is not evidence of a body-composition effect that the one-year trial failed to find.
5. Lipids and inflammation should not move much, and if they do it is probably not the anastrozole. Dougherty 2005 found no significant change in fasting lipids, hs-CRP, IL-6 or insulin sensitivity over 12 weeks in men. Draw a Lipid Panel, ApoB and hs-CRP at baseline and 12 weeks anyway, because the ATAC table records hypercholesterolemia in 9% U.S. Food and Drug Administration 2011 and because the one signal that did appear was triglycerides tracking estradiol (P = 0.04) — meaning triglycerides should fall slightly as estradiol falls, and a rise points at something else in the stack.
What nobody has tested yet
Nobody has run anastrozole against placebo in a man on exogenous testosterone. That is the entire use case on this site and it has never been studied. The trial is straightforward: men on a stable testosterone dose, randomized to anastrozole or placebo, with sensitive estradiol, hematocrit, lipids and a DEXA at baseline and 6 months. Until it exists, every dosing convention in this space is extrapolated from 37 and 88 older men with intact axes Leder 2004 Burnett-Bowie 2009.
Nobody has validated a target estradiol in men against an outcome. People titrate to a number, and the number came from a reference range built on assays of varying quality, not from a trial that showed a particular estradiol produced better bone, better libido or fewer events. The published male trials did not target an estradiol at all — they used a fixed dose and reported where estradiol landed.
Nobody has studied the micro-dose. The lowest dose ever tested in men is 1 mg twice weekly Leder 2004. The community standard of 0.25 mg twice weekly is a quarter of that, is entirely unstudied, and is pharmacologically plausible only because the 50-hour half-life U.S. Food and Drug Administration 2011 makes accumulation do the work. A simple dose-ranging study using sensitive estradiol as the endpoint would settle it in six weeks.
Nobody knows whether testosterone replacement rescues the bone loss. Burnett-Bowie 2009 showed spine BMD falling when anastrozole raised testosterone and lowered estradiol at the same time — which is the strongest available evidence that in men it is estradiol, not testosterone, that holds the skeleton up. Whether adding exogenous testosterone on top changes that, and at what estradiol, has not been measured in anyone.
Anastrozole — its own safety story, not its class's
The bone cost is real, it is measured, and it happened in a trial where testosterone went up. One year of 1 mg daily in men aged 60+ lowered posterior-anterior spine bone mineral density against placebo, P = 0.0014, while placebo drifted upward Burnett-Bowie 2009. The label records the same direction in women: a mean decrease in both lumbar spine and total hip BMD from baseline U.S. Food and Drug Administration 2011, and fractures in 10% of the ATAC anastrozole arm. Anyone running this for more than a few months without a baseline DEXA, vitamin D, calcium and loading exercise is accepting a documented cost without measuring it.
Joint pain is the most common reason people stop, and it has a number. Arthralgia in 15% of the ATAC anastrozole arm U.S. Food and Drug Administration 2011. It is the class effect of low estrogen rather than a quirk of this molecule, which is why switching aromatase inhibitors usually does not fix it and lowering the dose sometimes does.
Cholesterol: a difference against tamoxifen, not a rise on its own. Elevated serum cholesterol was reported in 9% on anastrozole versus 3.5% on tamoxifen U.S. Food and Drug Administration 2011; the 12-week male trial found no significant lipid change at all Dougherty 2005. The honest reading is that tamoxifen is lipid-protective and anastrozole is neutral, not that anastrozole is harmful to lipids.
What it does not do. It has no detectable effect on the formation of adrenal corticosteroids or aldosterone U.S. Food and Drug Administration 2011. That is a genuine safety advantage over the first-generation inhibitors and it is why no steroid cover is required.
The real failure mode in this population is over-suppression, and it looks like the problem it was meant to fix. Estradiol in men maintains bone, lipids, libido, mood and joint comfort. Crushed estradiol produces joint pain, flat libido, low mood and accelerating bone loss — a symptom set almost identical to the low-testosterone state people take testosterone for. The only thing that distinguishes them is a sensitive estradiol result on the same draw as the testosterone, which is why this page keeps insisting on both. And one more thing the trials say plainly: raising testosterone this way for a year produced no change in body composition or strength Burnett-Bowie 2009. The drug controls a hormone; it does not build anything.
Sources read for this page
- U.S. Food and Drug Administration. ARIMIDEX (anastrozole) tablets, for oral use - full prescribing information (NDA 020541).. FDA approved labeling, revision 2011
- Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.. J Clin Endocrinol Metab 2004 · PMID 15001605
- Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.. Clin Endocrinol (Oxf) 2009 · PMID 18616708
- Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.. J Clin Endocrinol Metab 2009 · PMID 19820017
- Dougherty RH, Rohrer JL, Hayden D, Rubin SD, Leder BZ. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.. Clin Endocrinol (Oxf) 2005 · PMID 15670201
Anastrozole — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Two different mechanisms with one shared consequence: less estrogen signaling. Aromatase inhibitors (anastrozole, exemestane) stop testosterone converting to estradiol; SERMs (tamoxifen, raloxifene, clomiphene, enclomiphene) block or activate the receptor depending on the tissue.
- The predicted harm is the same either way and it is not the one people expect. Estrogen is not a side effect to be eliminated — it is required for bone density, joint comfort, lipid handling, libido and mood in men as well as women. Crushing it produces aching joints, flat libido, low mood and, over years, measurable bone loss.
- Clomiphene specifically is a mixture of two isomers and the longer-lived one (zuclomiphene) accumulates; the visual disturbances reported on it are attributed to that accumulation. Enclomiphene is the isolated isomer, which is the entire argument for it.
What has actually been reported
- Well documented in oncology use: hot flushes, joint pain and reduced bone mineral density on AIs; venous thromboembolism and endometrial changes on tamoxifen.
- Visual disturbance on clomiphene is uncommon but real and is a reason to stop rather than push through.
How to reduce the risk
Same mechanism as the prediction.
- The dose almost everyone gets wrong is the AI dose. These are used in oncology to drive estradiol as close to zero as possible; that is a cancer-treatment goal and it is the wrong target for anyone else. Most people feeling terrible on a protocol are over-suppressing estradiol.
- Measure before adjusting, and measure with the sensitive (LC-MS/MS) estradiol assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
- If an AI is genuinely needed, the lowest effective dose intermittently beats a fixed daily one. Bone density is worth tracking on anything run for more than a year.
What it does to your bloodwork
A fact about the assay.
- Sensitive estradiol, total and free testosterone, LH and FSH, a lipid panel, and — for long-term use — a DEXA for bone density.
Don't run this if
- You are only using one because of a number rather than a symptom. An estradiol reading with no symptoms attached is not a reason to medicate.
The honest unknown
- Long-term outcomes of AI use in otherwise healthy men, at the doses used outside oncology, have not been studied. The bone and lipid consequences are extrapolated from populations taking them for a different reason.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Anastrozole — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Anastrozole moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Anastrozole in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Anastrozole
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Estradiol, Sensitive (LC/MS-MS) | Standard E2 assays are unreliable in men — this is the one to use |
| Total Testosterone | The other half of the ratio you're actually managing |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Low estradiol worsens lipids. This is the cost of over-suppressing |
| Osteocalcin | Bone turnover. Men need estradiol for bone, and AIs remove it |
The TRT Monitoring panel covers these in one order — 9 markers, $198.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Anastrozole — frequently asked questions
What is Anastrozole?
Anastrozole (Arimidex) is a hormonal & sexual research compound. Non-steroidal aromatase inhibitor — lowers estrogen by blocking testosterone-to-estrogen conversion.
Is the full Anastrozole protocol on this page?
The reported research dose is on this page, along with how Anastrozole works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Anastrozole?
Anastrozole has an approximate half-life of ~48 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Anastrozole?
Current evidence level: Human (established). Anastrozole is offered for research purposes only and is not an approved medicine.
Anastrozole inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Anastrozole is used for
Anastrozole appears under 2 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Anastrozole is the aromatase arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.